Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Coeptis Therapeutics Holdings, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...|
Docs:
|
"License Agreement, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc",
"Sublicense Agreement, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc",
"Asset Purchase Agreement, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc",
"Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics" |
|
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement by and between Coeptis Therapeutics Holdings, Inc. and Ladenburg Thalmann & Co. Inc",
"Warrant Agency Agreement, by and between Coeptis Therapeutics Holdings, Inc. and Continental Stock Transfer & Trust Company",
"Form of Pre-Funded Warrant",
"Form of Series A Warrant",
"Form of Series B Warrant",
"Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering WEXFORD, Pa., June 14, 2023 -- Coeptis Therapeutics Holdings, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of 2,150,000 shares of common stock, 1,350,000 pre-funded warrants, 3,062,500 Series A Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date, and 3,062,500 Series B Warrants with an exercise price of $1.65 per share and a term of five years fol...",
"Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering WEXFORD, Pa., June 16, 2023 -- Coeptis Therapeutics Holdings, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the closing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and commissions and offering expenses. The offering was comprised of 2,150,000 shares of common stock, 1,350,000 pre-funded warrants, 3,062,500 Series A Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date, and 3,062,500 Series B Warrants with an exercise price of $1.65 per share and a term of five years fo..." |
|
| 06/09/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 05/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/31/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/29/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/26/2022 |
8-K
| Quarterly results |
| 07/06/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 04/27/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 04/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 12/20/2021 |
8-K
| Quarterly results |
| 11/16/2021 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 10/22/2021 |
8-K
| Quarterly results |
| 09/03/2021 |
8-K
| Quarterly results |
| 05/28/2021 |
8-K
| Quarterly results |
| 05/14/2021 |
8-K
| Quarterly results |
| 12/15/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/09/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/03/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...|
Docs:
|
"Underwriting Agreement, by and among the Company and Imperial Capital LLC",
"Amended and Restated Memorandum and Articles of Association",
"Warrant Agreement, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent",
"Letter Agreement, by and among the Company, its officers, directors and Bull Horn Holdings Sponsor LLC",
"Investment Management Trust Agreement, October 29, 2020, by and between the Company and Continental Stock Transfer & Trust Company, as trustee",
"Registration Rights Agreement, by and among the Company and certain security holders",
"Private Placement Warrants Purchase Agreement, by and between the Company and Imperial Capital LLC, I-Bankers Securities, Inc. and Northland Securities, Inc",
"Private Placements Warrants Purchase Agreement, by and between the Company and Bull Horn Holdings Sponsor LLC",
"Form of Indemnity Agreement, by and between the Company and each of its officers and directors",
"Form of Subscription Agreement, by and between the Sponsor and each Anchor Investor" |
|
|
|